Core Viewpoint - The company Baiaosaitu-B (02315) is expected to report significant growth in its 2025 fiscal year, with a projected revenue of approximately 1.379 billion RMB, representing a year-on-year increase of 40.63% [1] Financial Performance - The net profit attributable to the company's owners is projected to be 173 million RMB, showing a remarkable year-on-year growth of 416.37% [1] - The net profit attributable to the company's owners, excluding non-recurring gains and losses, is expected to be 116 million RMB, reflecting a year-on-year increase of 405.39% [1] - Total assets of the group are anticipated to reach 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - The equity attributable to the company's owners is projected to be 2.175 billion RMB, which is a significant increase of 160.76% from the beginning of the period [1] Growth Drivers - The growth in the company's operating performance is primarily attributed to the continuous expansion in overseas markets, coupled with the recovery of the domestic biopharmaceutical industry [1] - The company maintains a strategy of driving performance growth through innovation, supported by sustained high-intensity R&D investment to build core technological barriers [1] - Lean management practices are being implemented to continuously enhance operational efficiency, which contributes to the rapid improvement of the company's profitability [1]
百奥赛图-B(02315)发布2025年度业绩快报 归母净利润1.73亿元 同比增长416.37%